Drug resistance in pathogenic protozoa is very often caused by changes to the ‘transportome’ of the parasites. In *Trypanosoma brucei*, several transporters have been implicated in uptake of the main classes of drugs, diamidines and melaminophenyl arsenicals. The resistance mechanism had been thought to be due to loss of a transporter known to carry both types of agents: the aminopurine transporter P2, encoded by the gene *TbAQP1*. However, although loss of P2 activity is well-documented as the cause of resistance to the veterinary diamidine diminazene aceturate (DA; Berenil®), cross-resistance between the human-use arsenical melarsoprol and the diamidine pentamidine (melarsoprol/pentamidine cross resistance, MPXR) is the result of loss of a separate high affinity pentamidine transporter (HAPT1). A genome-wide RNAi library screen for resistance to pentamidine, published in 2012, gave the key to the genetic identity of HAPT1 by linking the phenomenon to a locus that contains the closely related *T. brucei* aquaglyceroporin genes *TbAQP2* and *TbAQP3*. Further analysis determined that knockdown of only one pore, *TbAQP2*, produced the MPXR phenotype. *TbAQP2* is an unconventional aquaglyceroporin with unique residues in the “selectivity region” of the pore, and it was found that in several MPXR lab strains the WT gene was either absent or replaced by a chimeric protein, recombined with parts of *TbAQP3*. Importantly, wild-type *AQP2* was also absent in field isolates of *T. b. gambiense*, correlating with the outcome of melarsoprol treatment. Expression of a wild-type copy of *TbAQP2* in even the most resistant strain completely reversed MPXR and re-introduced HAPT1 function and transport kinetics. Expression of *TbAQP2* in *Leishmania mexicana* introduced a pentamidine transport activity indistinguishable from HAPT1. Although *TbAQP2* has been shown to function as a classical aquaglyceroporin it is now clear that it is also a high affinity drug transporter, HAPT1. We discuss here a possible structural rationale for this remarkable ability.

**Keywords:** *Trypanosoma brucei*, aquaporin, aquaglyceroporin, drug transport, pentamidine, melarsoprol, drug resistance, HAPT1

**INTRODUCTION**

African trypanosomes are extracellular parasites, which circulate in the bloodstream and tissue fluids of their mammalian hosts and are transmitted by tsetse flies in sub-Saharan Africa. They are responsible for the human disease sleeping sickness, or human African trypanosomiasis (HAT), caused by two subspecies of *Trypanosoma brucei*: *T. b. gambiense* causes the chronic form of the disease in West and Central Africa, and is responsible for the vast majority of disease cases (Brun et al., 2010), whilst *T. b. rhodesiense* causes the acute form in East Africa. Both are widely believed to be fatal unless adequate treatment is provided. The number of cases has recently decreased due to increased surveillance, treatment of cases, and targeting of the insect vector.

Both forms of HAT comprise two stages: stage one where the parasites spread through the haemo-lymphatic system from the site of the tsetse bite and stage two where the parasites cross into the cerebro-spinal fluid (CSF) via the blood-CSF and blood-brain barrier and establish an infection in the central nervous system (CNS; Mogk et al., 2014). If left untreated, the disease caused by either species leads to coma and death (Brun et al., 2010).

Most trypanosomes have to survive within two hosts, mammalian and insect, necessitating adaption to differing nutritional environments, and remodelling of their surface coat (Gadelha et al., 2011); and must also live within two specialized environments in their mammalian host. In the bloodstream and lymphatic system the parasites evade both the acquired and innate immune systems, predominantly by antigenic variation, changing the variant surface glycoprotein (VSG) expressed on their surface to avoid antibody-mediated responses (Gadelha et al., 2011). During the second stage of infection, in the CNS, they are more protected from the immune system, and may exist as a reservoir, able to reinfect the bloodstream, for example after treatment with drugs which do not penetrate into the CSF (Mogk et al., 2014).

The closely related, but human serum sensitive species *T. congolense*, *T. vivax*, and *T. brucei brucei* cause the veterinary disease animal African trypanosomiasis (AAT) or nagana, a severe, often
failing, wasting disease, principally affecting cattle, but also importantly sheep and goats, and which renders livestock farming across the tsetse belt of Africa extremely challenging (Steverding, 2008). T. vivax can also be transmitted mechanically by bloodsucking insects, and such transmission has been found in Central and South America (Gonzatti et al., 2014), and in non-tsetse infested regions of Ethiopia (Cherenet et al., 2006; Fikru et al., 2012). The disease Surra, a similar wasting disease to nagana, is caused by T. evansi, which has lost its maxicircle kinetoplast DNA and thus the procyclic stage of its lifecycle, and as such does pass through an insect vector, instead being mechanically transmitted between hosts by blood-feeding insects (Lun et al., 2010). It is the most widely distributed animal trypanosomiasis, being found in Asia, northern and northeastern Africa, Central America and South America, within a variety of host species, mainly causing disease in horses, camels, and water buffaloes, although it can also affect other equines, cattle, goats, sheep, elephants, cats, and dogs (Desquesnes et al., 2013; Namangala and Odongo, 2014). A further trypanosomiasis of horses and donkeys, dourine, is caused by the related species, T. equiperdum, which also cannot pass through an insect vector, being instead, uniquely amongst trypanosomal diseases, transmitted though sexual contact (Lun et al., 2010). It causes a variety of genito-urinary symptoms, along with anaemia and emaciation, leading to nervous symptoms (Namangala and Odongo, 2014).

TREATMENT OF HAT

There are currently five treatment options for HAT: pentamidine, suramin, melarsoprol, eflornithine monotherapy, and nifurtimox–eflornithine combination therapy (NECT); which drug is used is mostly dependent on disease stage and the infecting subspecies, as well as on availability of the medication. Pentamidine is used for early stage HAT caused by T. b. gambiense; whilst early stage T. b. rhodesiense is treated with suramin (Brun et al., 2010). Both were introduced in the early 20th century, with pentamidine discovered in 1937 and suramin in 1916 (Delespaux and de Koning, 2007; Steverding, 2008).

For patients with second-stage disease, melarsoprol has been widely used as the first line drug for decades, despite the fact that the drug causes fatal reactive encephalopathy in 2–5% of patients depending on the infective species (Brun et al., 2010), possibly due to rapid lysis of large amounts of parasites in the brain. Over the last 15 years, increasing rates of melarsoprol treatment failures have also been reported, with rates between 20 and 39% being seen in some foci of infections in Uganda, Republic of South Sudan, Angola, and the Democratic Republic of Congo (DRC; Legros et al., 1999; Brun et al., 2001; Moore and Richer, 2001; Stanghellini and Josenando, 2001; Robays et al., 2008; Mumba Ngoyi et al., 2010).

Eflornithine was introduced in 1990, and has been freely available since 2001 (Simarro et al., 2012), but despite the increasing failures of melarsoprol treatment, it did not replace melarsoprol as a first line treatment due to a number of significant problems: it is only effective against T. b. gambiense parasites, it is expensive and requires logistically difficult administration procedures, requiring four daily intravenous infusions for 14 days (Simarro et al., 2012). Partly due to the ease of inducing eflornithine resistance in the laboratory (Vincent et al., 2010) and anecdotal reports of eflornithine treatment failures, clinical trials were conducted to assess the efficacy of combinations of eflornithine, melarsoprol and the oral drug nifurtimox, which is commonly used to treat Chagas disease (Simarro et al., 2012). Ultimately, after phase III trials, the combination of nifurtimox and eflornithine (or NECT) was found to have the same safety and efficacy as eflornithine treatment alone, but to have the significant advantages of reducing both the dose and treatment time necessary for cure and of being less likely to induce resistance than eflornithine mono-therapy (Priotto et al., 2009). Thus, the World Health Organization (WHO, 2009) recommended that NECT should be used for treatment of second-stage T. b. gambiense sleeping sickness, and melarsoprol use has rapidly declined. Although between 2001 and 2006 the number of T. gambiense cases treated with eflornithine only increased from 3 to 12%, by 2009 the proportion treated was 66% and after NECT was added to the WHO essential medicines list in 2009 the proportion treated with this combination increased to 88% in 2010 (Simarro et al., 2012). Melarsoprol does of course remain the only treatment available for late-stage T. b. rhodesiense HAT, making study of the mechanisms of resistance crucial.

TREATMENT OF AAT

Currently three drugs are most commonly used for AAT: the diamidine compound dimazene aceturate (DA), and the phenanthridines isometamidium chloride (ISM) and ethidium bromide; although ISM is principally used prophylactically (Delespaux et al., 2008). The effective treatment of livestock remains hugely important for farmers within the tsetse belt of Africa, with an estimated 46 million head of cattle at risk of trypanosomiasis (Swallow, 2000). The disease is controlled by both vector control and chemotherapy, with an estimated 35 million doses of trypanocides administered annually (Geerts and Holmes, 1998), although the effectiveness of all trypanocides is threatened by drug resistance (Geerts et al., 2001; Delespaux et al., 2008).

DRUG RESISTANCE AND TRANSPORTERS

TBA1/P2

Melarsoprol/pentamidine cross resistance (MPXR) is a well-known phenomenon in HAT, first described by Rollo and Williamson (1951); and although the cause was never completely resolved, it has long been clear that it was linked to reduced drug accumulation (Damper and Patton, 1976; Frommel and Balber, 1987; de Koning, 2001a). The first drug transporter identified in trypanosomes was the P2 adenosine/adenine transporter, which was originally connected to melarsoprol uptake (Carter and Fairlamb, 1993) and subsequently to diamidine transport (Barrett et al., 1995; Carter et al., 1995, 1999; de Koning and Jarvis, 2001; de Koning et al., 2004). The P2 gene was the first nucleoside transporter to be cloned from trypanosomes, with the gene designated as TbaT1 (Mäser et al., 1999). Although the evidence for diamidine and arsenical transport by TbaT1/P2 is unquestionable, it has become equally clear that TbaT1/P2 mediates only a proportion of the uptake of both diamidines and arsenicals (de Koning, 2001b; Bray et al., 2003). The proportion of uptake varies
in particular for different diamidines, as the deletion of *TbA T1* led to a high level of resistance to the veterinary diamidine DA (Matovu et al., 2003) and the newer clinical candidates furamidine and CPD0801 (Ward et al., 2011), but only to a minor loss of sensitivity for melaminophenyl arsenicals and for pentamidine (Matovu et al., 2003; Bridges et al., 2007). Thus, *T. brucei* is sensitive to these diamidines only because it expresses this unique adenosine/adine transporter – a very rare example of a transporter with virtually equal affinity and transport efficiency for a nucleoside and its nucleobase (de Koning et al., 2005). The *TbA T1* allele may be the random result of extensive gene duplication, as the *T. brucei* genome contains at least 15 genes of the equilibrative nucleoside transporter (ENT) family (de Koning et al., 2005). Interestingly, the related parasite *T. congolense*, which is a major pathogen of livestock in sub-Saharan Africa, also has a major amplification of the ENT family (up to 19 members), but phylogenetically most of these cluster as nucleobase transporters rather than nucleoside transporters (P1-cluster) or nucleoside/nucleobase transporters (P2 cluster; Munday et al., 2013). As such, *T. congolense* does not have a counterpart of *TbA T1* (Munday et al., 2013) and is much less sensitive to diminazene (Munday and De Koning, in preparation), although this is the main drug for the treatment of *T. congolense* infection.

The mode by which *TbA T1* recognizes substrates as different as diminazene, adenosine, melarsoprol, adenosine and pentamidine, while displaying total selectivity for aminopurines (adenosine/adenine) over oxopurines (inosine, hypoxanthine, guanosine, guanine) has been investigated in detail. From an initial analysis of substrate selectivity, using purine analogs, it was clear that the main recognition site was the so-called ‘amidine’ motif =N-CH(R)-NH2 consisting of N1 and the 6-position amine group of the purine ring (Carter et al., 1999; de Koning and Jarvis, 1999). Substrate recognition was modelled in great detail using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices analysis (CoMSIA), which produced a predictive pharmacophore model using a very diverse dataset of binding energies for 112 compounds (Collar et al., 2009).

The functional loss of *TbAT1* has been linked to drug resistance in *T. brucei* species, starting with the seminal paper by Carter and Fairlamb (1993) showing that trypanosomes resistant to melaminophenyl arsenicals had lost ‘an unusual adenosine transporter.’ This transporter was cloned by Mäser et al. (1999) and a ‘resistance allele’ with several single nucleotide polymorphisms was linked to the failure to sensitize cells to the arsenicals. Similar mutations were also detected in clinical isolates and linked to high levels of melarsoprol failure in Uganda (Matovu et al., 2001). However, it has become clear that the model for melarsoprol resistance is more complicated (de Koning, 2008; Baker et al., 2013), with loss of at least one additional transporter necessary for the high-resistance phenotype (Bridges et al., 2007).

**ADDITIONAL PENTAMIDINE/ARSENCAL TRANSPORTERS IN T. brucei**

Studies with [125I]-iodopentamidine showed that only half the pentamidine transport capacity of *T. brucei* is sensitive to inhibition by adenosine or adenine, and identified an additional low affinity pentamidine transporter, LAP1 (de Koning and Jarvis, 2001). A further high affinity pentamidine transport activity, HAPT1, was identified using [3H]-pentamidine of high specific activity, which allowed the very low substrate concentrations required to detect this transport activity (de Koning, 2001b). This established a model of three pentamidine transporters with *Km* values of approximately 35 nM (HAPT1), 300 nM (P2), and 35 μM (LAPT1; de Koning, 2008). HAPT1 was additionally found to be a transporter for the arsenicals, with the loss of both the *TbA T1* and HAPT1 transporters simultaneously leading to high-level MPXR (Bridges et al., 2007; de Koning, 2008), and also to mediate a small proportion of diminazene uptake (Teka et al., 2011), although the latter is clinically insignificant. The very low flux of diminazene through HAPT1, relative to *TbAT1*, shows that this transporter is far more selective in the transport of diamidines. We have observed that, particularly, diamidines that lack a flexible linker chain between the benzamidine end groups tend to be poorly recognized and transported by HAPT1 (Ward et al., 2011), which helps explain the much higher activity of pentamidine than diminazene against *T. brucei* species.

**EFLORNITHINE TRANSPORTER**

Transporters were similarly found to be crucial for sensitivity and resistance to another essential anti-trypanosomal drug, eflornithine. The *T. brucei* transporter of eflornithine, AA T6, was identified in 2010 via metabolomic analysis of eflornithine-resistant parasites, which indicated a low level of eflornithine in the resistant parasites, and the subsequent sequencing of the predicted *T. brucei* amino acid transporter genes, which found that the locus of *TbAA T6* and several adjacent genes was lost in the resistant line. The identification of *TbAA T6* as the transporter of eflornithine was confirmed using specific gene knockdown with RNA-interference (RNAi), which resulted in resistance to eflornithine. Moreover, the expression of *TbAA T6* in an eflornithine-resistant line reversed the resistance phenotype (Vincent et al., 2010). Two RNAi library screens also identified *TbAA T6* as the transporter of eflornithine and the main determinant of resistance to the drug (Baker et al., 2011; Schumann Burkard et al., 2011). *TbAA T6* was subsequently confirmed to be a functional amino acid transporter, with its expression allowing growth of *Saccharomyces cerevisiae* mutants on neutral amino acids (Mathieu et al., 2014).

**AQUaporins IN T. brucei**

There are three aquaglyceroporins in the *T. brucei* genome, AQP1-3, which transport a number of traditional aquaglyceroporin substrates, including water, glycerol, urea, dihydroacetone (Uzcátegui et al., 2004), and ammonia (Zeuthen et al., 2006), as well as the trivalent metalloids arsenite and antimonite (Uzcátegui et al., 2013). The relatively high number of AQPs expressed in *T. brucei* and other extracellular parasites has been hypothesized to be due to their need to survive in the extracellular environment, and/or to the differentiation between the different parasitic lifecycle stages necessary for survival in both mammalian and sandfly hosts, with the accompanying morphological and functional changes to their surface membranes (Song et al., 2014). The three *T. brucei* aquaporins have differing localisations, with *TbAQP1* located on the flagellar membrane, *TbAQP3*
on the plasma membrane (Bassarak et al., 2011) and TbAQP2 in the flagellar pocket in bloodstream form parasites and on the plasma membrane in procyclic-form parasites (Baker et al., 2012). Interestingly, TbAQP2 and TbAQP3 are not essential for \textit{in vivo} replication, nor indeed for testes-mediated transmission, as \textit{in vivo} drug pressure can lead to the loss of these genes (see below).

**UNUSUAL PORE OF TbAQP2**

TbAQP2 contains non-standard motifs in key portions of the gene which are thought to determine the selectivity of the pore, whereas AQP3 has standard selectivity region amino acids. TbAQP2 is the only Major Intrinsic Protein (MIP) family member so far described that has NSA/NPS and IVLL motifs, whilst TbAQP3 and TbAQP1 both contain the classical NPA/NPA motifs present in most other family members (Baker et al., 2012), and a WGYR motif in the selectivity region common to 118 aquaglyceroporin-type pores (Baker et al., 2013). Particularly, the absence of the aromatic/arginine (ar/R) motif in AQP2 may lead to an increase in its ability to transport larger and charged molecules as has been found for mammalian aquaporin 1 (Beitz et al., 2006; Li et al., 2011; Rambow et al., 2014).

**LOSS OF TbAQP2 CAUSES MELARSOPROL-PENTAMIDINE CROSS RESISTANCE (MPXR)**

\textit{T. brucei} aquaporins 2 and 3 were initially identified as being potentially important for MPXR by an RNAi library screen. The two genes are arranged on chromosome 10 in a tandem array and share 83% sequence identity (Alsfeld et al., 2012). By expressing each gene separately in aqp2–aqp3 double null cells, it was shown that TbAQP2 was the determinant for pentamidine and arsenical sensitivity/resistance (Baker et al., 2012).

The open reading frame of \textit{Tbaqp2} in B48 was investigated in the well-characterized laboratory-selected strain B48, which has high levels of resistance to both pentamidine and melarsoprol, having had \textit{Tbat1} deleted by homologous recombination and lost HAP1 due to continuous passage in increasing concentrations of pentamidine (Bridges et al., 2007). In this strain a \textit{Tbaqp2}-3.569−841 \textsuperscript{1} chimeric gene, inactive with respect to pentamidine sensitivity and transport, was found to have replaced \textit{Tbaqp2}; a 272-bp section toward the 3′ end of \textit{Tbaqp2} was replaced in-frame with the corresponding section of \textit{Tbaqp3} (Baker et al., 2012), see \textbf{Figures 1A,B}. This suggested that it was this latter section of the gene which is at least partially responsible for the drug-sensitivity profile of \textit{Tbaqp2}, and this section does include the second half of the likely selectivity region (NPS/IVLL is replaced with the classical regions of NPA/IGYR in the chimera). The chimeric gene was found to have assumed the location pattern of \textit{Tbaqp3}, being found across the whole plasma membrane (Munday et al., 2014).

\textsuperscript{1}As multiple different chimeric AQP2/3 chimeric genes are being reported in connection with (potential) drug resistance, it is important to have a nomenclature that unambiguously identifies each isolate. In brackets the first numbers indicate the first nucleotide that is unambiguously AQP3 sequence; the second number is the first nucleotide after that to be unambiguously AQP2 sequence. If there is no second number the sequence reads as AQP3 to the end.

The aquaporins present in other lab-derived MPXR strains, produced by selection with the water-soluble derivative of melarsoprol, cymelarsan, have also been assessed. In the \textit{T. b. gambiense} line 386-Mr, the \textit{Tbaqp2} gene was completely absent (\textbf{Figure 1D}); whilst in the \textit{T. b. brucei} 247-Mr line a different chimera, \textit{Tbaqp2}3.569(841), had been produced via the loss of both wild-type \textit{Tbaqp2} and \textit{Tbaqp3} (\textbf{Figure 1C}) The 247-Mr chimera was in frame, comprised of the first 363 bp of \textit{Tbaqp2} and the last 576 bp of \textit{Tbaqp3}; thus the protein contains both of the NPA/NPA selectivity motifs of \textit{Tbaqp3}. In a further two MPXR strains, produced by \textit{in vivo} selection of the \textit{T. b. rhodesiense} strain STIB900 to grow in either pentamidine or melarsoprol, the \textit{Tbaqp2} genes were found to be absent altogether (Munday et al., 2014; \textbf{Figure 1D}).

**RE-EXPRESSION OF TBAQP2 REVERSES MPXR**

Re-expression of \textit{Tbaqp2} in B48 cells re-established the sensitivity of the parasites to pentamidine and cymelarsan and restored the missing HAP1 activity; expression of \textit{Tbaqp2} in \textit{Leishmania mexicana} promastigotes also introduced HAP1 function, with kinetic parameters indistinguishable from those obtained in \textit{T. brucei}, and greatly sensitized the parasites to pentamidine and cymelarsan. In contrast, expression of the chimeric \textit{Tbaqp2}-3.569−841 gene from the B48 strain in \textit{Tbaqp2} null parasites had no significant effect on the sensitivity of the parasites to pentamidine and cymelarsan, showing that \textit{Tbaqp2}-3.569−841 is not a functional pentamidine/cymelarsan transporter (Munday et al., 2014), although it is as yet unclear whether it forms a functional aquaporin.

**TBAQP2 IN FIELD ISOLATES**

The above studies established that \textit{Tbaqp2} encodes the HAP1 transport activity, and that alterations in the \textit{Tbaqp2} locus were the main determinant of MPXR in lab-derived strains. However, it was vital to verify whether \textit{Tbaqp2} defects also contribute to MPXR in field isolates; this has now been completed in two separate studies, using \textit{T. gambiense} isolates which were found to have reduced melarsoprol sensitivity in \textit{in vivo} tests (Graf et al., 2013; Pyana Pati et al., 2014). Firstly, the \textit{Tbaqp2-AQP3} locus was genotyped in a number of \textit{T. gambiense} field isolates (both recent and historical; from patients who either relapsed or were cured after melarsoprol treatment). In the five recent isolates from the Mbuji-Masi focus in the DRC, which were isolated from patients who relapsed after melarsoprol treatment, a single in-frame, chimeric \textit{Tbaqp2}-3.814 gene was found instead of the native tandem gene locus (Graf et al., 2013). The first 813 bp of the chimera were from \textit{Tbaqp2}, with the remaining 126 bp end of \textit{Tbaqp3}. In this chimera, the putative NSA/NPS selectivity region of \textit{Tbaqp2} is retained, see \textbf{Figure 1E}. In an older isolate from South Sudan, K03048, heterozygosity in the locus was observed; one allele contained only \textit{Tbaqp3}, having lost \textit{Tbaqp2}, whilst the other allele was composed of a similar \textit{Tbaqp2}-3.814 chimera to that found in the DRC strains (\textbf{Figures 1D,E}). This South Sudanese isolate was also from a patient who relapsed after melarsoprol treatment. The wildtype \textit{Tbaqp2} allele was found in a number of older strains, isolated from 1960 to 1995, which came from patients either successfully cured by melarsoprol.
FIGURE 1 | Schematic of the documented AQP2 and AQP3 loci in lab-derived and field-isolated strains of Trypanosoma brucei. Brown lines = SNPs in chimeras compared to WT; yellow lines = position of NSA/NPS loci from TbAQP2; pink lines = position of NPA/NPA loci from TbAQP3. (A) Locus found in wildtype strains (T. b. brucei Lister 427, 247, and TREU927; T. b. gambiense 386, STIB 930, and DAL972; and T. b. rhodesiense STIB900 (minor differences in TbAQP3 are not highlighted); (B) Locus with chimera TbAQP2-3(814−841) from lab-derived pentamidine resistant strain B48 (Baker et al., 2012); (C) Locus of chimera TbAQP2-3(814−841) from lab-derived melarsoprol resistant strain 247-Mr (Munday et al., 2014); (D) Locus in lab-derived melarsoprol resistant strains 386-Mr and STIB900-Mr; and lab-derived pentamidine resistant strain STIB900-PR (Munday et al., 2014), and in one T. b. gambiense K03048 allele (Graf et al., 2013); (E) Locus with chimera TbAQP2-3(814), found in field isolates from Mbuji-Masi locus in DRC and the other K03048 allele (Graf et al., 2013; Pyana Pati et al., 2014); (F) Locus with chimera TbAQP2-3(880), found in all T. b. gambiense field strains from Mbuji-Masi (Pyana Pati et al., 2014); (G) Locus with chimera TbAQP2-3(880), found in two old Congolese T. b. gambiense field strains, MBA and KEMLO (Pyana Pati et al., 2014) and (H) Chimera TbAQP2-3(617−658), without loss of AQP3, from four T. b. gambiense field strains isolated in Masi-Manimba (Pyana Pati et al., 2014).
their trypanosomiasis by melarsoprol treatment and appear to be heterozygous, containing both a TbAQP2 gene which contains 18 single nucleotide polymorphisms (SNPs) compared to that found in the wild-type *T. b. gambiense* strain STIB930, as well as a chimera of the first 616 bp of TbAQP2 (with two SNPs), a 41 bp region of *TbAQP3* and the last 282 bp of TbAQP2 (Pyana Pati et al., 2014; Figure 1H). This TbAQP2-3\(\text{-}617\)–658 chimera from the Masi-Manimba focus retains the potential NSA/NPS selectivity region of TbAQP2, providing a potential explanation for the assumed sensitivity of these strains to melarsoprol treatment.

So far, it has not been investigated whether the various chimeras found in these *T. b. gambiense* field isolates are capable of transporting pentamidine or melarsoprol, and further expression studies are necessary. However, in all the lab-derived and field isolates with reduced sensitivity to, or relapse after treatment with, melarsoprol and/or pentamidine TbAQP2 has been found to be altered in some way. In the isolates from some cured patients the wild-type TbAQP2 was present, although with a number of SNPs, alongside a TbAQP2-3 chimera, which retains the unusual selectivity region of TbAQP2. At least one of the chimeras, from the lab-derived resistant strain, has been shown to be incapable of transporting pentamidine; and thus TbAQP2 appears to be a determinant of the efficacy of pentamidine and melaminophenyl arsicals.

**SELECTIVITY FILTER**

The organization of the AQP2/AQP3 locus in the various strains so far investigated is shown in Figure 1. In many cases TbAQP2 has been recombined into a chimera gene that possesses most of the AQP3 selectivity filter. Thus, the potential of the selectivity regions to determine the MPXR has been investigated (Munday et al., 2014). Synthetic genes encoding either the B48 chimera TbAQP2-3\(\text{-}569\)–841 or TbAQP3 containing the selectivity region of TbAQP2 were expressed in the *aqp2/aqp3* null line; only for the TbAQP2-3\(\text{-}569\)–841 chimera (which already contains the first part of the selectivity motif, as part of the first 561 bp of TbAQP2 in the chimeric protein), did introduction of the second TbAQP2 selectivity region affect sensitivity to cymelarsan, reaching susceptibility to this drug halfway between the *aqp2/aqp3* null and the same line expressing WT TbAQP2, indicating that more residues in the first portion of TbAQP2 are necessary than just the predicted selectivity region; this conclusion was underscored by the observation that the effect was only apparent for arsencial drug sensitivity and that pentamidine sensitivity was not affected by the change (Munday et al., 2014).

**MODELLING OF TbAQP2**

The predicted binding modes of pentamidine and melarsoprol are shown in Figures 2A,B, respectively. The two guanidine groups of pentamidine are predicted to interact with main-chain carbonyl oxygen atoms of residues located near both the extracellular and cytoplasmic side of the protein channel (Figure 2A). Similarly to pentamidine, one of the melamine amino substituents of melarsoprol is predicted to interact with main-chain carbonyl oxygen atoms of residues located near the extracellular side, whilst the hydroxyl group of melarsoprol is predicted to interact with the amide side-chain group of Asn130 (Figure 2B). The pore size of TbAQP2 is sufficiently large to accommodate either pentamidine or melarsoprol (Figure 2C), with both ligands able to assume distended conformations.

The tetrameric structure of the protein models of TbAQP2, TbAQP3, and TbAQP2-3\(\text{-}569\)–841 chimera are shown in Figures 3A–C, respectively. The key pore forming residues
All the drugs currently in use against trypanosomiasis were identified in Table 1 are also shown in Figure 3 in space-filling models. The structural alignment of these protein models suggests that TbAQP3 and the TbAQP2-3(569−841) chimera contain pore-forming residues which have bulkier side-chains than with TbAQP2. This could explain the lack of drug transport activity by TbAQP3 and TbAQP2-3(569−841) chimera given the predicted smaller pore in these subunits in comparison with TbAQP2. TbAQP3, at least, is known to retain normal transport functions for the much smaller water and glycerol substrates (Bassarak et al., 2011), as well as for inorganic As(III) and Sb(III) (Uzcátegui et al., 2013). In particular, TbAQP3 contains three residues (Trp102, Tyr250, and Arg256) whose side-chains protrude into the pore of the channel. These residues align with residues with smaller side-chains in TbAQP2 (Ile110, Leu258 and Leu264, respectively; Table 1; Figures 3A–C). Similarly, in the TbAQP2-3(569−841) chimera, Tyr258 and Arg264 are likely to be responsible for the lack of transport, as the side-chains of these residues are also predicted to protrude into the pore channel. These predictions are currently under experimental investigation using site-directed mutagenesis.

**CONCLUDING REMARKS**

All the drugs currently in use against trypanosomiasis were identified through in vitro disease models and/or phenotypic screens. To a large extent, these toxic chemicals, including diamidines, arsenicals, efornithine, and even suramin (Delepaux and de Koning, 2007; Alsford et al., 2012, 2013), act selectively on trypanosomes because of unique transport mechanisms, explaining the enormous differences in potency against the closely related *Leishmania* species. Just the expression of the single gene *TbAQP2* in *L. mexicana* promastigotes rendered these parasites 40-fold sensitive to pentamidine and >1000-fold more sensitive to Cymelarsan (Munday et al., 2014). Conversely, the same transporters that make the current chemotherapy against sleeping sickness possible are the cause of drug resistance when their activities are lost.

Thus, the main reason for the sensitivity of trypanosomes to the drugs used against them is that they have unique transporters, and although these transporters are easily recognized as being from ubiquitous gene families, there is currently no way to predict their unusual substrate specificity and role from their primary sequences. The drug transporters so far identified still function efficiently as would be expected from their homologs in other species: i.e., as a purine transporter (P2/TbAT1), an aquaglyceroporin (TbAQP2), and as an amino acid transporter (TbAAAT).

It is only because trypanosomal drug transport has been studied in the amount of detail that it has been, that the drug transporters so far identified still function efficiently as would be expected from their homologs in other species: i.e., as a purine transporter (P2/TbAT1), an aquaglyceroporin (TbAQP2), and as an amino acid transporter (TbAAAT). It is only because trypanosomal drug transport has been studied in the amount of detail that it has been, that the drug transporters so far identified still function efficiently as would be expected from their homologs in other species: i.e., as a purine transporter (P2/TbAT1), an aquaglyceroporin (TbAQP2), and as an amino acid transporter (TbAAAT).
As there are so many transporters in the \textit{T. brucei} genome it is possible to do this the other way round, i.e., to try to generate a drug that will enter trypanosomes through a specific transporter (Barrett and Gilbert, 2006; Vodnala et al., 2013). In such a scenario, given that loss of transporters has been demonstrated to give rise to resistance, it would be important to assess by how many transporters any new compounds are taken up; this could lead to minimisation of the risk of transporter-related resistance for new compounds, especially if the transporter, like any individual purine transporter, \textit{TbAQP2} or \textit{TbAAT6}, are non-essential. In each case a single point mutation (such as the introduction of a STOP codon or frame shift) could be sufficient to induce a high level of drug resistance, apparently with no fitness cost.

The unusual aquaglyceroporin \textit{TbAQP2} was found to encode the high affinity pentamidine transporter (HAPT1), (Munday et al., 2014), and appears to be vitally important for sensitivity to pentamidine and melaminophenyl arsenicals (Baker et al., 2012; Graf et al., 2013). It may be possible to test for MPXR by assessing the presence of wild-type \textit{TbAQP2} alleles in clinical samples. However, this is unlikely to deliver a simple test as there is no single, easily confirmed mutation and the emerging data suggest that many different mutations or rearrangements can give rise to loss of \textit{AQP2} as a drug transporter (Graf et al., 2013; Munday et al., 2014; Pyana Pati et al., 2014), it would probably require sequencing of the complete \textit{AQP2-AQP3} locus to identify any changes and adjust drug treatment plans accordingly.

By assessing the presence of wild-type \textit{TbAQP2} alleles in clinical samples. However, this is unlikely to deliver a simple test as there is no single, easily confirmed mutation and the emerging data suggest that many different mutations or rearrangements can give rise to loss of \textit{AQP2} as a drug transporter (Graf et al., 2013; Munday et al., 2014; Pyana Pati et al., 2014), it would probably require sequencing of the complete \textit{AQP2-AQP3} locus to identify any changes and adjust drug treatment plans accordingly.

By assessing the presence of wild-type \textit{TbAQP2} alleles in clinical samples. However, this is unlikely to deliver a simple test as there is no single, easily confirmed mutation and the emerging data suggest that many different mutations or rearrangements can give rise to loss of \textit{AQP2} as a drug transporter (Graf et al., 2013; Munday et al., 2014; Pyana Pati et al., 2014), it would probably require sequencing of the complete \textit{AQP2-AQP3} locus to identify any changes and adjust drug treatment plans accordingly.


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 05 January 2015; accepted: 05 February 2015; published online: 09 March 2015.


This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology.

Copyright © 2015 Munday, Settimo and de Koning. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.